
Greenwich LifeSciences, Inc.: shareholders and insiders
Price
$19.25
November 20, 2026Market cap $283M
What Ploutos Investor adds for Greenwich LifeSciences
Part of Ploutos Investor, €9.99 a month
- The full history: 7 fiscal years, from 2019
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The share price has risen 40% since Nov 16, 2026, when the 10-Q these figures come from was filed ($13.76 then, $19.25 on Nov 20, 2026). The figures date from before that move.10-Q
- The filings show substantial debt that is not stated in a form we can read. The debt, net cash, enterprise value, the multiples built on it and the return on invested capital would leave that debt out, so we leave them out.
Insiders and their shares
Purchases and sales by officers and directors from Nov 22, 2025 to Jul 30, 2026, from their own Form 4 filings.
Bought on the market
$475.7K
1 person
Sold on the market
–
nobody
From Nov 22, 2025 to Nov 22, 2026, the days the chart shows. Change its range and the figures follow.
How the sales were made, as a share of their value
No sales in the period.
By year
Insiders' open-market purchases (up) and sales (down), by value, since Nov 22, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.
2026·bought $230.6K by 1 person·no sales
- 2025: bought $245.1K by 1 person, no sales
- 2026: bought $230.6K by 1 person, no sales
- Jul 29, 2026Snehal PatelCEO and CFOKind
- Jul 28, 2026Snehal PatelCEO and CFOKind
- Jul 27, 2026Snehal PatelCEO and CFOKind
- Jul 24, 2026Snehal PatelCEO and CFOKind
- Jul 23, 2026Snehal PatelCEO and CFOKind
- Jan 13, 2026Snehal PatelCEO and CFOKind
- Jan 12, 2026Snehal PatelCEO and CFOKind
| Date | Person | Kind | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jul 29, 2026 | Snehal PatelCEO and CFO | 700 | $13.10 | $9.2K | Form 4 | |
| Jul 28, 2026 | Snehal PatelCEO and CFO | 1,500 | $13.59 | $20.4K | Form 4 | |
| Jul 27, 2026 | Snehal PatelCEO and CFO | 1,500 | $13.62 | $20.4K | Form 4 | |
| Jul 24, 2026 | Snehal PatelCEO and CFO | 1,100 | $12.88 | $14.2K | Form 4 | |
| Jul 23, 2026 | Snehal PatelCEO and CFO | 2,500 | $13.14 | $32.9K | Form 4 | |
| Jan 13, 2026 | Snehal PatelCEO and CFO | 1,800 | $29.83 | $53.7K | Form 4 | |
| Jan 12, 2026 | Snehal PatelCEO and CFO | 2,900 | $27.54 | $79.9K | Form 4 |
From the Form 4s insiders file with the SEC within two business days of each trade. Before Jul 27, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.
Insiders and their shares
Every buy and sale by GLSI's officers and directors from 2020 up to November 21, 2025, 6 more calendar years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 3 years.
and 1 more, back to 2020
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
No filing over 5%
Since Dec 18, 2024 nobody has filed a Schedule 13D or 13G for Greenwich LifeSciences shares.
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
No well-known manager
None of the managers we track held Greenwich LifeSciences shares in their latest 13F.
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 10.6% of its shares outstanding were held short, -1.8% since the report before.
- Shares held short
- 1.55M
- 10.6%
- Since the report before1.58M on Sep 30, 2026
- -1.8%
- 10.7
- 144.9K
- More days to cover thanof 4,578 US-listed companies with enough volume
- 93%
- Report date
- Oct 15, 2026
- Shares held short
- Oct 31, 2023: Shares held short 163.5K
- Nov 15, 2023: Shares held short 166.8K
- Nov 30, 2023: Shares held short 167.0K
- Dec 15, 2023: Shares held short 114.7K
- Dec 29, 2023: Shares held short 152.3K
- Jan 12, 2024: Shares held short 161.2K
- Jan 31, 2024: Shares held short 154.5K
- Feb 15, 2024: Shares held short 173.6K
- Feb 29, 2024: Shares held short 121.3K
- Mar 15, 2024: Shares held short 137.0K
- Mar 28, 2024: Shares held short 140.5K
- Apr 15, 2024: Shares held short 185.1K
- Apr 30, 2024: Shares held short 189.1K
- May 15, 2024: Shares held short 177.1K
- May 31, 2024: Shares held short 195.1K
- Jun 14, 2024: Shares held short 229.4K
- Jun 28, 2024: Shares held short 260.2K
- Jul 15, 2024: Shares held short 370.6K
- Jul 31, 2024: Shares held short 415.6K
- Aug 15, 2024: Shares held short 451.7K
- Aug 30, 2024: Shares held short 466.6K
- Sep 13, 2024: Shares held short 505.2K
- Sep 30, 2024: Shares held short 495.7K
- Oct 15, 2024: Shares held short 501.2K
- Oct 31, 2024: Shares held short 484.6K
- Nov 15, 2024: Shares held short 470.7K
- Nov 29, 2024: Shares held short 490.4K
- Dec 13, 2024: Shares held short 530.2K
- Dec 31, 2024: Shares held short 556.7K
- Jan 15, 2025: Shares held short 612.7K
- Jan 31, 2025: Shares held short 644.0K
- Feb 14, 2025: Shares held short 653.1K
- Feb 28, 2025: Shares held short 643.5K
- Mar 14, 2025: Shares held short 658.4K
- Mar 31, 2025: Shares held short 743.3K
- Apr 15, 2025: Shares held short 910.7K
- Apr 30, 2025: Shares held short 998.0K
- May 15, 2025: Shares held short 1.01M
- May 30, 2025: Shares held short 959.9K
- Jun 13, 2025: Shares held short 968.6K
- Jun 30, 2025: Shares held short 1.03M
- Jul 15, 2025: Shares held short 1.00M
- Jul 31, 2025: Shares held short 1.04M
- Aug 15, 2025: Shares held short 1.06M
- Aug 29, 2025: Shares held short 1.07M
- Sep 15, 2025: Shares held short 1.23M
- Sep 30, 2025: Shares held short 1.37M
- Oct 15, 2025: Shares held short 1.34M
- Oct 31, 2025: Shares held short 1.35M
- Nov 14, 2025: Shares held short 1.58M
- Nov 28, 2025: Shares held short 1.61M
- Dec 15, 2025: Shares held short 1.62M
- Dec 31, 2025: Shares held short 1.67M
- Jan 15, 2026: Shares held short 1.55M
- Jan 30, 2026: Shares held short 1.32M
- Feb 13, 2026: Shares held short 1.28M
- Feb 27, 2026: Shares held short 1.34M
- Mar 13, 2026: Shares held short 1.42M
- Mar 31, 2026: Shares held short 1.50M
- Apr 15, 2026: Shares held short 1.52M
- Apr 30, 2026: Shares held short 1.54M
- May 15, 2026: Shares held short 1.54M
- May 29, 2026: Shares held short 1.52M
- Jun 15, 2026: Shares held short 1.46M
- Jun 30, 2026: Shares held short 1.46M
- Jul 15, 2026: Shares held short 1.47M
- Jul 31, 2026: Shares held short 1.54M
- Aug 14, 2026: Shares held short 1.59M
- Aug 31, 2026: Shares held short 1.66M
- Sep 15, 2026: Shares held short 1.63M
- Sep 30, 2026: Shares held short 1.58M
- Oct 15, 2026: Shares held short 1.55M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading59.5% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 59.5% of the shares in the reported trades were short sales, against 69.0% in the 14 before.
- Last 14 sessionsNov 3, 2026 – Nov 20, 2026
- 59.5%
- The 14 beforeOct 14, 2026 – Nov 2, 2026
- 69.0%
- Change
- -9.5 pts
- Short sales a dayon average, of 115.8K shares
- 68.9K
- More than atof 3,666 US-listed companies, same days
- 81%
- Median of alleight in ten from 34.4% to 63.9%
- 50.5%
- Short sales
- Oct 14, 2026: Short sales 59.7%
- Oct 15, 2026: Short sales 71.7%
- Oct 16, 2026: Short sales 73.8%
- Oct 19, 2026: Short sales 92.3%
- Oct 20, 2026: Short sales 50.5%
- Oct 21, 2026: Short sales 68.9%
- Oct 22, 2026: Short sales 76.8%
- Oct 23, 2026: Short sales 74.4%
- Oct 26, 2026: Short sales 90.3%
- Oct 27, 2026: Short sales 58.8%
- Oct 28, 2026: Short sales 52.8%
- Oct 29, 2026: Short sales 63%
- Oct 30, 2026: Short sales 58.4%
- Nov 2, 2026: Short sales 70.8%
- Nov 3, 2026: Short sales 76.8%
- Nov 4, 2026: Short sales 75.5%
- Nov 5, 2026: Short sales 72.2%
- Nov 6, 2026: Short sales 68.1%
- Nov 9, 2026: Short sales 57.2%
- Nov 10, 2026: Short sales 60.8%
- Nov 11, 2026: Short sales 52.3%
- Nov 12, 2026: Short sales 43%
- Nov 13, 2026: Short sales 69.7%
- Nov 16, 2026: Short sales 69.9%
- Nov 17, 2026: Short sales 53.6%
- Nov 18, 2026: Short sales 52.7%
- Nov 19, 2026: Short sales 54.6%
- Nov 20, 2026: Short sales 78.3%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
What the insiders hold
The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.
A lower bound: it counts only the 2 officers and directors with a market trade since Nov 23, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.
The ETFs that hold it
Which of the 349 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- IWCiShares Micro-Cap ETFWeight in the fund0.04%
- IWOiShares Russell 2000 Growth ETFWeight in the fund0.01%
- IWMiShares Russell 2000 ETFWeight in the fund0.01%
- VTWOVanguard Russell 2000 Index FundWeight in the fund0.00%
- VXFVanguard Extended Market Index FundWeight in the fund0.00%
- VTIVanguard Total Stock Market Index FundWeight in the fund0.00%
6 of the 349 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 51
- Q4 2025: Managers 50
- Q1 2026: Managers 64
- Q2 2026: Managers 58
Institutional investors by quarter
The fund managers holding GLSI, quarter by quarter, from Q3 2020 to Q2 2025, 20 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 58 managers held 1.69M shares, worth $40M. During the quarter 7 opened a position, 13 closed one, 22 added and 14 trimmed.
The largest holders, Q2 2026
- BlackRockIn the quarter+12%
- Vanguard Capital ManagementIn the quarter-6.7%
- Geode Capital ManagementIn the quarter+8.2%
- State StreetIn the quarter+6.9%
- Vanguard Portfolio ManagementIn the quarter+37%
- Northern TrustIn the quarter+6.8%
- Bank of New York MellonIn the quarter+3.0%
- Vanguard Fiduciary TrustIn the quarter+2.4%
- Morgan StanleyIn the quarter+46%
- Goldman Sachs GroupIn the quarter-0.5%
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| BlackRock | 485.9K | +12% | $11M |
| Vanguard Capital Management | 278.2K | -6.7% | $6.5M |
| Geode Capital Management | 168.2K | +8.2% | $3.9M |
| State Street | 143.1K | +6.9% | $3.4M |
| Vanguard Portfolio Management | 80.9K | +37% | $1.9M |
| Northern Trust | 80.2K | +6.8% | $1.9M |
| Bank of New York Mellon | 47.9K | +3.0% | $1.1M |
| Vanguard Fiduciary Trust | 46.0K | +2.4% | $1.1M |
| Morgan Stanley | 43.4K | +46% | $1.0M |
| Goldman Sachs Group | 39.3K | -0.5% | $922.7K |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do Greenwich LifeSciences's filings show?
Who buys and sells is one part of Greenwich LifeSciences's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have GLSI's insiders bought or sold?
From Jul 27, 2026 to Jul 30, 2026 Greenwich LifeSciences's insiders bought $97.0K and sold 0 of shares on the market. – of the sales were under set 10b5-1 plans.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.